RetaMaps

Aurora Bariatric & Weight Management Clinic

Aurora Sinai Medical Center — Bariatric & Weight Management · 945 North 12th Street · Milwaukee, WI 53233

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • GLP-1 medications named on site
  • Medically supervised weight loss
  • Nutrition support

About this practice

Aurora Health Care’s Bariatrics & Surgical Weight Loss program is an MBSAQIP-accredited hospital service offering gastric sleeve and Roux-en-Y gastric bypass, with a multidisciplinary team of surgeons, nurse practitioners, and physician assistants. Locations include Aurora Sinai Medical Center in Milwaukee (945 N 12th Street) plus Summit, Oshkosh, and Green Bay. Official pages emphasize surgical weight loss and also describe medical weight-management support (nutrition, activity, and behavioral change); they do not name semaglutide or tirzepatide.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visits—
Cash pay acceptedYes
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Nearby providers in Milwaukee

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs